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Abstract
Ovarian cancer is one of the most deadly malignancies in women because of its poor prognosis and that a majority 
of patients are diagnosed at advanced stage. Therefore, chemotherapy becomes the most important treatment option 
in most ovarian cancer cases. However, chemoresistance in relapsed cases is the major obstacle for the clinical 
management of this disease. Mounting evidences have suggested the de novo (intrinsic) and acquired (extrinsic) 
chemoresistance are two major underlying mechanisms occurring in human cancers. The de novo chemoresistance 
is attributed to the existence of cancer stem cells, while the genetic and/or epigenetic alterations in dysregulation of 
oncogenes or tumor suppressor genes contribute to the acquired chemoresistance. In this review, we will summarize 
and discuss the recent findings of the above mechanisms in chemoresistance and particularly, we will focus on 
the significance of putative miRNAs expressions and their associated signaling regulations in the development of 
acquired chemoresistance in ovarian cancer.
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Editorial
Ovarian cancer is one of the most leading fetal gynaecological 
malignance in women worldwide [1,2]. The high mortality rate of 
this disease is because of its poor prognosis and that approximately 
75% of the patients are diagnosed at advanced stages (FIGO stages 
III and IV). Therefore, adjuvant chemotherapy is necessary for the 
clinical management of patients with advanced tumors [3]. Platinum-
based combination chemotherapy is the standard first-line strategy 
for ovarian cancer patients. Although initial treatment achieves high 
percentage in responses, most of the patients will eventually develop 
resistance to anti-cancer drugs [4,5]. Therefore, chemoresistance 
is the major clinical obstacle for the treatment of ovarian cancer 
patients nowadays. Mounting evidences have documented that de 
novo (intrinsic) and acquired (extrinsic) chemoresistance are two 
major most likely mechanisms in various human cancers. However, 
the precise mechanism for chemoresistance in ovarian cancer remains 
unclear.
The de novo  chemoresistance, also called as intrinsic 
chemoresistance, refers to cancer cells that are resistant to 
chemotherapeutic drugs from the very beginning of anti-cancer 
drug treatment. This type of chemoresistance originates from cells 
which have already had capacities of drug-resistance such as limiting 
drugs uptake, enhancing efflux, or activating detoxification of 
drugs [6]. Previous studies reported that the aberrant expressions of 
certain crucial proteins could lead to intrinsic chemoresistance. For 
instance, the reduced expression of BNIP3 (Bcl2/adenovirus E1B 19 
kDa protein interacting protein) and increased expression of ISG15 
(Interferon-Stimulated Gene 15) were associated with intrinsic 
gemcitabine resistance in pancreatic cancer patients [7,8]. Up to date, 
researchers have summarized that this subset of tumor cells with 
resistant properties against anti-cancer drugs is Cancer Stem Cells 
(CSC), which are also known as tumor initiating cells. This type of 
cells shows high cell survival rate under chemotherapeutic challenge, 
faster proliferation and high spreading capacity. Researchers believe 
such CSCs are responsible for the abilities of tumorigenesis, self-
renewal, differentiation and chemo/radio-resistance [9,10]. A very 
recent report showed that MYC-driven murine tumors contained a 
subset of cells that refluxed Hoechst 33342. Such onco-genotype of the 
hepatic tumor could promote a specific mechanism of chemoresistance 
that contributed to the survival of hepatic CSCs [11]. This evidence 
suggests that CSCs contribute to intrinsic chemoresistance in human 
cancer. However, the characteristics of CSCs and their functions in 
chemoresistance of a wide range cancer types need more evidences to 
prove and elucidate [12-14]. 
On the other hand, the mechanism of acquired chemoresistance, 
which is also called extrinsic chemoresistance, includes genetic and 
epigenetic alternations of crucial genes in cancer cells during the 
repetitive treatment of chemotherapy. The genetic and epigenetic 
changes in cells may gradually induce cancer cells to adapt the 
apoptotic stresses of anti-cancer drugs [15]. In ovarian cancer, the 
first-line chemotherapy with a combination of platinum-paclitaxel 
yields response rates of more than 80%; with 40–60% cases have 
complete response in advanced ovarian cancer. However, the median 
progression-free survival is only 18 months as most of these patients 
relapse ultimately [16]. Re-treating these patients with the same drugs 
(carboplatin and paclitaxel) always confers response rates of around 
50% in tumors that relapse more than 12 months after initial treatment. 
But this falls to 10–20% when the treatment-free interval is less than 6 
months [17]. This indicates that the chemoresistance of ovarian cancer 
is likely due to the existence of acquired chemoresistance.
Although the underlying mechanism leading to acquired 
chemoresistance is still unclear, numerous studies have documented 
that genetic or epigenetic alterations are frequently occurred and are 
the cause of chemorsistance development in cancers. The reasons are 
attributed to the mechanisms of most anti-cancer drugs for inhibiting 
cancer cell growth through impairing DNA synthesis, damaging the 
DNA in the nucleus or breaking down the mitotic spindles of the 
cells. These effects could cause genetic and epigenetic changes in gene 
expressions. Genetic changes refer to the changes in DNA sequence, 
including mutation, deletion, amplification, translocation, and so 
on. When these changes happen to genes, such as TP53, RB1 and 
KRAS, which are significant for controlling cell cycle, proliferation, 
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survival and apoptosis etc, they make cancer cells aggressive and 
chemoresistant [18-20]. Recently, abundant evidences have showed 
that the genetic alternations could be one of the causes of the acquired 
resistance in human ovarian cancer. For example, Shim et al. [21] 
reported that an elevation of a transcription factor NF-E2-Related 
Factor-2 (NRF2) activity might be a determining factor for resistance to 
doxorubicin in ovarian carcinoma cell lines and the adaptive activation 
of the NRF2 system could participate in the development of acquired 
resistance to anthracycline therapy. Fu et al. [22] found that the 
enhanced expression of Glycogen Synthase Kinase-3α (GSK-3α) was 
associated with acquired resistance to paclitaxel in ovarian carcinoma 
cells. Moreover, Ong et al. [23] using microarray analysis in a newly 
established arsenic-resistant ovarian cancer cell line OVCAR-3/AsR 
revealed that there was a dysregulation of multiple genes associated 
with the development of acquired chemoresistance to As(2)O(3) and 
increased tumor aggressiveness.
In the past few decades, emerging evidences have documented 
that the epigenetic alterations could be the novel mechanism leading 
to the acquired chemoresistance. Epigenetic changes, including DNA 
methylation, histone modifications and microRNA regulation, regulate 
crucial gene expressions critically in the development of drug-resistance 
[24-26]. Initially, researchers have focused on DNA methylation and 
histone modifications for gene expression regulation. This is because 
DNA hypermethylation, together with histone methylation and/
or histone deacetylation, in the promoter region cause chromosome 
remodeling and further inhibit the binding of transcription factors to 
the promoter region. This induces gene silence in the transcriptional 
level [27,28]. For instance, hypermethylation in the transcription factor 
AP2E downregulated its expression, induced overexpression of DKK4 
and further made colorectal cancer patients suffer to ineffectiveness to 
fluorouracil-based chemotherapy [29]. In ovarian cancer cells, MutL 
Hhomolog 1 (MLH1) and TAp73 are two well-known examples silenced 
by methylation and such gene silencing confers ovarian cancer cells to 
be acquired drug resistance [30,31]. Indeed, the recent comprehensive 
studies in methylation have been conducted and several drugs, such as 
5-azacitidine (Aza) and hydralazine, have been used in clinical trials 
for tackling chemoresistance in human cancers [32,33], suggesting the 
DNA methylation is one of the major causes in chemoresistance. 
Recently, researchers have found another type of epigenetic 
changes, microRNA (miRNA) playing a crucial role in gene regulation 
and chemoresistance. MiRNAs refer to a group of small, non-coding 
RNAs that bind to the 3’UTR of their target mRNAs under base 
complementarity via the miRNAs seed sequence. This induces the 
target mRNA degradation or translational repression, depending on 
the complementary level of the binding between miRNA and its target 
mRNAs [34,35]. Indeed, it’s well known that the regulation of miRNA 
plays an important role in the cell development and differentiation 
during embryonic development. In contrast, deregulation of miRNAs 
usually contributes to various diseases including cancers [36,37]. 
Emerging evidences have suggested that the deregulation of miRNAs is 
closely associated with the acquired chemoresistance in various human 
cancers including ovarian cancer. For example, up-regulation of miR-
21 enforced its function in HER2+ BT474, SKBR3, and MDA-MB-453 
breast cancer cells that were induced to the acquired trastuzumab 
resistance by long-term exposure to trastuzumab antibody [38]. In 
addition, loss of MiR-181a and miR-630 expressions might inhibit 
cisplatin-induced cancer cell death in Non Small Cell Lung Cancer 
(NSLC) [39]. Moreover, a recent study reported that the upregulation 
of miR-214 and miR-376c induced cell proliferation, cell survival 
and cisplatin resistance in ovarian cancer [40,41]. Therefore, further 
investigation of miRNA deregulation is a need to unveil the mechanism 
of chemoresistance in human cancers including ovarian cancer.
As the base complementarity between miRNA and its binding to 
the 3’UTR of mRNAs is not necessary to be 100%, one miRNA may 
regulate numerous target mRNAs. Hence, one miRNA may be involved 
in governing a network of signaling pathways such as the TGF-β, WNT 
and EGF signaling cascades. Considering these pathways act as very 
important roles in regulating cell proliferation, apoptosis, DNA repair 
etc., the deregulation of miRNAs expressions could cause dysfunction 
of these pathways in regulating cellular physiology and properties 
including increased resistance to anti-cancer drugs induced cell 
apoptosis [42-44]. There are several well-known pathways regulated 
by miRNAs found in ovarian cancer chemoresistance, such as PI3K/
AKT/mTOR and Phosphatase and Tensin Homolog (PTEN) signaling 
cascades [45,46]. For example, Nagaraja et al. [47] found that miR-22 
and miR-100 repressed AKT/mTOR signaling and enhanced sensitivity 
to the rapamycin analog RAD001 (everolimus) in clear cell ovarian 
cancer. In addition, Fu et al. [48] also found that miR-93 was inversely 
correlated with PTEN expression in CDDP-sensitive and induced 
resistant human ovarian cancer cells by activation of AKT signaling 
pathway. Apart from the above pathways, NOTCH signaling is one of 
the most famous pathways for the development of chemoresistance 
in various human cancers including ovarian cancer. The conserved 
ligand-receptor NOTCH, governing its signaling factors such as the 
HES family and the HEY family, plays critical roles in cell proliferation, 
survival, apoptosis as well as resistance to anti-cancer drugs [49-51]. 
Numerous reports found that miR-34 participated in the Notch pathway 
regulation and involved in the acquired drug resistance in prostate 
cancer and breast cancer, suggesting that miRNA mediated NOTCH 
signaling activity was involved in chemoresistance of cancers [52,53]. 
NOTCH pathway contains abundant signaling factors for regulating its 
gene expression and cross-talking with Wnt and Hedgehog pathways, 
indicating miRNAs modulate not only NOTCH but also other signaling 
pathways [54,55]. Apart from NOTCH pathway, recent findings also 
raise the importance of FOXM1 transcription factor network in human 
cancers including ovarian cancer [49]. Our laboratory have previously 
revealed that the aberrant activation of FOXM1 signaling cascade 
triggered cell migration in ovarian cancer cells, suggesting that FOXM1 
was associated with aggressive chemoresistant ovarian cancer [56]. 
Therefore, further investigations in miRNAs regulating of NOTCH 
and FOXM1 pathways may provide new insights in the mechanism 
of chemoresistance and assist in exploring molecular therapeutic 
strategies in ovarian cancer. 
In conclusion, although recent studies have suggested that 
the acquired resistant mechanism is the major chemoresistance 
in ovarian cancer, further investigations to support this notion is 
needed. Moreover, the understanding of miRNA regulated signaling 
pathways controlling cell proliferation, apoptosis, DNA repair 
etc. such as NOTCH and FOXM1 pathways may provide valuable 
insights in the molecular mechanisms of the development of acquired 
chemoresistance. 
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